Usana on the Edge in China, St. Jude Okays Repurchase: Healthcare Business Report

Usana Health Sciences (NASDAQ:USNA) does not have a “direct sales” license for its dietary supplement products in China, says Citron Research, but at least it does not risk legal recourse for doubtful marketing boasting, as does Nu Skin. The research firm adds that “You simply won’t believe how Usana is establishing and maintaining huge numbers of ‘sales associates’ in mainland China.”

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >

St. Jude Medical (NYSE:STJ) said in a Thursday press release that its Board has okayed a share buyback of as much as $1 billion of its outstanding common stock, with the repurchases occuring at such times and prices as the management sees fit. As of November 28th, the firm had around 308 million shares of common stock issued and outstanding.

Pfizer’s (NYSE:PFE) Pfizer Oncology will present updated data in chronic myeloid leukemia for its oral Abl and Src kinase inhibitor, Bosulif (bosutinib), which was recently okayed by the FDA, along with new data in acute lymphoblastic leukemia and non-Hodgkin’s lymphoma for inotuzumab ozogamicin, a CD-22 directed antibody drug conjugate which is currently being evaluated in two Phase 3 trials, at the 54th Annual Meeting of the American Society of Hematology, on December 8th through the 11th.

Don’t Miss: Retailers Hit Hard by Sandy and Weak Consumer.